Metastatic breast cancer: We do need primary cost data

Breast

Volumn 21, Issue 3, 2012, Pages 384-388

  Bonastre, J ^a   Jan, P ^a   Barthe, Y ^a   Koscielny, S ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

Lifetime costs; Metastatic breast cancer; Primary cost data

Indexed keywords

CISPLATIN; DOCETAXEL; DOXORUBICIN; FLUOROURACIL; GEMCITABINE; PACLITAXEL; TRASTUZUMAB;

ADULT; AGE; AGED; ARTICLE; BREAST METASTASIS; CANCER GRADING; CANCER LOCALIZATION; CANCER PALLIATIVE THERAPY; CANCER PROGNOSIS; CANCER RECURRENCE; COHORT ANALYSIS; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DEATH; DRUG COST; ETHNIC GROUP; FEMALE; FRENCH LANGUAGE; HISTOPATHOLOGY; HOSPITAL COST; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MEDICAL RECORD; PRIORITY JOURNAL; SURVIVAL TIME;

EID: 84862521248     PISSN: 09609776     EISSN: 15323080     Source Type: Journal    
DOI: 10.1016/j.breast.2012.03.012     Document Type: Article

References (14)

1. Belot A., Grosclaude P., Bossard N., Jougla E., Benhamou E., Delafosse P., et al. Cancer incidence and mortality in France over the period 1980-2005. Rev Epidemiol Sante Publique 2008, 56:159-175.
2. Early Breast Cancer Trialists' Collaborative Group Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005, 365:1687-1717.
3. Koscielny S., Arriagada R., Adolfsson J., Fornander T., Bergh J. Impact of tumour size on axillary involvement and distant dissemination in breast cancer. Br J Cancer 2009, 101:902-907.
4. Perez E.A. Breast cancer management: opportunities and barriers to an individualized approach. Oncologist 2011, 16:20-22.
5. Thomas R.J., Williams M., Glen J., Callam M. Comparing the cost of adjuvant anastrozole with the benefits of managing less patients with relapsed breast cancer. Breast Cancer Res Treat 2009, 117:289-295.
6. Hurley S.F., Huggins R.M., Snyder R.D., Bishop J.F. The cost of breast cancer recurrences. Br J Cancer 1992, 65:449-455.
7. Bercez C., Lebrun T., Bonneterre M.E., Selke B., Lenne X., Bonneterre J. Advanced breast cancer: an evaluation of the cost of recurrence. Bull Cancer 1999, 86:585-590.
8. Stokes M.E., Thompson D., Montoya E.L., Weinstein M.C., Winer E.P., Earle C.C. Ten-year survival and cost following breast cancer recurrence: estimates from SEER-medicare data. Value Health 2008, 11:213-220.
9. Thomas R.J., Williams M., Marshall C., Glen J., Callam M. The total hospital and community UK costs of managing patients with relapsed breast cancer. Br J Cancer 2009, 100:598-600.
10. Dahlberg L., Lundkvist J., Lindman H. Health care costs for treatment of disseminated breast cancer. Eur J Cancer 2009, 45:1987-1991.
11. Long J., Ervin L. Using heteroscedasticity-consistent standard errors in the linear regression model. Am Statistician 2000, 54:217-224.
12. Will B.P., Berthelot J.M., Le Petit C., Tomiak E.M., Verma S., Evans W.K. Estimates of the lifetime costs of breast cancer treatment in Canada. Eur J Cancer 2000, 36:724-735.
13. Berkowitz N., Gupta S., Silberman G. Estimates of the lifetime direct costs of treatment for metastatic breast cancer. Value Health 2000, 3:23-30.
14. The SEER web site [accessed 24.09.11]. http://seer.cancer.gov/data/access.html.